Patent ID: 6251391
Filing Date: 2001-06-26
Classification: A23L,A61K,A61P,C12Y

Abstract:
A treatment composition able to reduce opioid-related symptoms in a human patient of an exorphin selected from the group consisting of a gluteomorphin comprising an amino acid sequence of Gly-Tyr-Tyr-Pro-Thr (SEQ ID NO:2) and a casomorphin comprising the amino acid sequence Tyr-Pro-Phe-Pro (SEQ ID NO:1), comprising a physiologically effective amount of a purified casomorphinase comprising dipeptidyl peptidase IV, a physiologically effective amount of a purified gluteomorphinase comprising tyrosinase or phenylalaninase, and at least one of the group consisting of a physiologically acceptable carrier, adjuvant, excipient, buffer and diluent.